biguanides has been researched along with Inflammation in 12 studies
Biguanides: Derivatives of biguanide (the structure formula HN(C(NH)NH2)2) that are primarily used as oral HYPOGLYCEMIC AGENTS for the treatment of DIABETES MELLITUS, TYPE 2 and PREDIABETES.
biguanides : A class of oral hypoglycemic drugs used for diabetes mellitus or prediabetes treatment. They have a structure based on the 2-carbamimidoylguanidine skeleton.
Inflammation: A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The effects of chlorhexidine on the appearance of leukocytes and some hydrolytic enzymes were studied in an experimental acute nonmicrobial inflammation reaction caused by implanation of viscose sponge beneath the backskin." | 7.66 | Effect of chlorhexidine gluconate on acute nonmicrobial inflammation reaction. ( Knuuttila, ML; Mielityinen, H; Paunio, KU, 1978) |
| " Our aim was to assess the clinical efficacy of a propylbetaine-polihexanide (PP) solution versus normal saline (NS) solution in WBP, assessing inflammatory signs and wound size reduction in patients with pressure ulcers (PUs) or vascular leg ulcers." | 5.22 | Effect of a wound cleansing solution on wound bed preparation and inflammation in chronic wounds: a single-blind RCT. ( Bellingeri, A; Chiari, P; Falciani, F; Moscatelli, A; Peghetti, A; Russo, A; Tino, G; Traspedini, P, 2016) |
| "The effects of chlorhexidine on the appearance of leukocytes and some hydrolytic enzymes were studied in an experimental acute nonmicrobial inflammation reaction caused by implanation of viscose sponge beneath the backskin." | 3.66 | Effect of chlorhexidine gluconate on acute nonmicrobial inflammation reaction. ( Knuuttila, ML; Mielityinen, H; Paunio, KU, 1978) |
| " No sign of infection or adverse event was observed after treatment with both dressings." | 2.87 | Inflammatory reaction, clinical efficacy, and safety of bacterial cellulose wound dressing containing silk sericin and polyhexamethylene biguanide for wound treatment. ( Ampawong, S; Angspatt, A; Aramwit, P; Harnsilpong, T; Napavichayanun, S, 2018) |
| "Insulin treatment in patients with type 2 diabetes mellitus affects the expression of inflammatory cytokines and subsequently modifies the thrombotic mechanisms in patients with coronary atherosclerosis, independently from the duration of diabetes and the extend of coronary artery disease." | 2.73 | Effects of insulin dependence on inflammatory process, thrombotic mechanisms and endothelial function, in patients with type 2 diabetes mellitus and coronary atherosclerosis. ( Antoniades, C; Bosinakou, E; Latsios, G; Marinou, K; Papageorgiou, N; Siasos, G; Stefanadi, E; Stefanadis, C; Tentolouris, C; Tousoulis, D; Tsioufis, C, 2007) |
| "The TIME acronym (tissue, infection/inflammation, moisture balance and edge of wound) was first developed more than 10 years ago, by an international group of wound healing experts, to provide a framework for a structured approach to wound bed preparation; a basis for optimising the management of open chronic wounds healing by secondary intention." | 2.48 | Extending the TIME concept: what have we learned in the past 10 years?(*). ( Carville, K; Drake, R; Fletcher, J; Leaper, DJ; Schultz, G; Swanson, T, 2012) |
| "In patients with type 2 diabetes mellitus, the traditional method of initiating therapy with a sulfonylurea and increasing the dosage until maximum levels are reached before adding an insulin-sensitizing agent has persisted and should be re-evaluated." | 2.42 | A comparison of agents used to manage type 2 diabetes mellitus: need for reappraisal of traditional approaches. ( Bell, DS, 2004) |
| " For the in vitro cytotoxic test with L929 mouse fibroblast cells, our novel dressing was not toxic to the cells and also promoted cell migration as good as the commercially available dressing, possibly due to the component of sericin released." | 1.43 | The safety and efficacy of bacterial nanocellulose wound dressing incorporating sericin and polyhexamethylene biguanide: in vitro, in vivo and clinical studies. ( Aramwit, P; Napavichayanun, S; Yamdech, R, 2016) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (16.67) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (16.67) | 29.6817 |
| 2010's | 6 (50.00) | 24.3611 |
| 2020's | 2 (16.67) | 2.80 |
| Authors | Studies |
|---|---|
| Park, CM | 1 |
| Kim, HY | 1 |
| Jeon, D | 1 |
| Shin, YJ | 1 |
| Kim, IH | 1 |
| Choi, SJ | 1 |
| Kim, KC | 1 |
| Lee, K | 1 |
| Kim, SH | 1 |
| Kim, MS | 1 |
| Nii, T | 1 |
| Yumoto, H | 1 |
| Hirota, K | 1 |
| Miyake, Y | 1 |
| Lakhani, BK | 1 |
| Thajudeen, B | 1 |
| Jawaid, I | 1 |
| Attzs, MS | 1 |
| Maharajan, VS | 1 |
| Napavichayanun, S | 2 |
| Ampawong, S | 1 |
| Harnsilpong, T | 1 |
| Angspatt, A | 1 |
| Aramwit, P | 2 |
| Yamdech, R | 1 |
| Bellingeri, A | 1 |
| Falciani, F | 1 |
| Traspedini, P | 1 |
| Moscatelli, A | 1 |
| Russo, A | 1 |
| Tino, G | 1 |
| Chiari, P | 1 |
| Peghetti, A | 1 |
| Kim, HR | 1 |
| Shin, DY | 1 |
| Chung, KH | 1 |
| Leaper, DJ | 1 |
| Schultz, G | 1 |
| Carville, K | 1 |
| Fletcher, J | 1 |
| Swanson, T | 1 |
| Drake, R | 1 |
| Bell, DS | 1 |
| Antoniades, C | 1 |
| Tousoulis, D | 1 |
| Marinou, K | 1 |
| Papageorgiou, N | 1 |
| Bosinakou, E | 1 |
| Tsioufis, C | 1 |
| Stefanadi, E | 1 |
| Latsios, G | 1 |
| Tentolouris, C | 1 |
| Siasos, G | 1 |
| Stefanadis, C | 1 |
| Knuuttila, ML | 1 |
| Paunio, KU | 1 |
| Mielityinen, H | 1 |
| Hamp, SE | 1 |
| Rosling, B | 1 |
| Lindhe, J | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Prospective Study of Quality of Life in Patients With Chronic Leg Wound(s) Treated With Prontosan® Wound Irrigation Solution and Prontosan® Wound Gel[NCT03369756] | 43 participants (Actual) | Interventional | 2018-02-20 | Terminated (stopped due to Terminated due to prolonged subject recruitment) | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"The Wound-QoL is a tool to measure disease-specific, health-related quality of life of patients with chronic wounds. It consists of 17 items on impairments which is assessed for the previous 7 days and is competed by the patient. It has 3 subscales that can assess Body, Psyche and Everyday Life. It can be used in clinical and observational studies and in daily practice.~Subscale Body consists of Items #1 to #5. Each individual item is rated on a scale ranging from 0 (not at all) to 4 (very much). The average of the subscale can be computed if no more than 1 item of the subscale is missing. The higher values represents more of an impact to the patient for that item." (NCT03369756)
Timeframe: 5 weeks overall (4 weeks of treatment and/or observations followed by a one-day visit at end of study in week 5)
| Intervention | score on a scale (Mean) | |||
|---|---|---|---|---|
| Body Subscore change, Baseline / Week 1 to Week 2 | Body Subscore change, Baseline / Week 1 to Week 3 | Body Subscore change, Baseline / Week 1 to Week 4 | Body Subscore change, Baseline / Week 1 to End / Week 5 | |
| Prontosan Solution and Gel | -0.76 | -0.93 | -1.19 | -1.17 |
"The Wound-QoL is a tool to measure disease-specific, health-related quality of life of patients with chronic wounds. It consists of 17 items on impairments which is assessed for the previous 7 days and is competed by the patient. It has 3 subscales that can assess Body, Psyche and Everyday Life. It can be used in clinical and observational studies and in daily practice.~Subscale Everyday Life consists of Items #Items #11 to #16. Each individual item is rated on a scale ranging from 0 (not at all) to 4 (very much). The average of the subscale can be computed if no more than 1 item of the subscale is missing. Generally, the higher values represents more of an impact to the patient for that item." (NCT03369756)
Timeframe: 5 weeks overall (4 weeks of treatment and/or observations followed by a one-day visit at end of study in week 5)
| Intervention | score on a scale (Mean) | |||
|---|---|---|---|---|
| Everyday Life Subscore change, Baseline / Week 1 to Week 2 | Everyday Life Subscore change, Baseline / Week 1 to Week 3 | Everyday Life Subscore change, Baseline / Week 1 to Week 4 | Everyday Life Subscore change, Baseline / Week 1 to End / Week 5 | |
| Prontosan Solution and Gel | -0.58 | -0.82 | -1.11 | -1.00 |
"The Wound-QoL is a tool to measure disease-specific, health-related quality of life of patients with chronic wounds. It consists of 17 items on impairments which is assessed for the previous 7 days and is competed by the patient. It has 3 subscales that can assess Body, Psyche and Everyday Life. It can be used in clinical and observational studies and in daily practice.~Subscale Psyche consists of Items #Items #6 to #10. Each individual item is rated on a scale ranging from 0 (not at all) to 4 (very much). The average of the subscale can be computed if no more than 1 item of the subscale is missing. The higher values represents more of an impact to the patient for that item." (NCT03369756)
Timeframe: 5 weeks overall (4 weeks of treatment and/or observations followed by a one-day visit at end of study in week 5)
| Intervention | score on a scale (Mean) | |||
|---|---|---|---|---|
| Psyche Subscore change, Baseline / Week 1 to Week 2 | Psyche Subscore change, Baseline / Week 1 to Week 3 | Psyche Subscore change, Baseline / Week 1 to Week 4 | Psyche Subscore change, Baseline / Week 1 to End / Week 5 | |
| Prontosan Solution and Gel | -0.77 | -1.04 | -1.24 | -1.26 |
Change in wound size from Baseline/Week 1 to Final/Week 5. The change in the size of a wound will be evaluated using a disposable ruler to directly measure the overall wound dimensions at each scheduled visit to the study site (Weeks 1 and 5). These measurements will be done before any cleaning of the wound and after cleaning the wound (debridement). (NCT03369756)
Timeframe: 5 weeks overall (4 weeks of treatment and/or observations followed by a one-day visit at end of study in week 5)
| Intervention | wound surface area (cm^2) (Mean) | |
|---|---|---|
| Pre-Debridement Wound Size Change (Baseline/Week 1 to Week 5 / End) | Post-Debridement Wound Size Change(Baseline/Week 1 to Final/Week 5) | |
| Prontosan Solution and Gel | -6.6 | -8.2 |
"The Wound-QoL is a tool to measure disease-specific, health-related quality of life of patients with chronic wounds. It consists of 17 items on impairments which is assessed for the previous 7 days and is competed by the patient. It has 3 subscales that can assess Body, Psyche and Everyday Life. These subscales cover items 1 to 16. Item 17 is not part of any of the subscales. The Wound-QoL can be used in clinical and observational studies and in daily practice.~Each individual item is rated on a scale ranging from 0 (not at all) to 4 (very much). A Total or Global score is the average of at least 13 completed questions, regardless of which questions were not completed. The average of each of the 3 subscales can be computed if no more than 1 item of the subscale is missing. The higher values represents more of an impact to the patient for that item." (NCT03369756)
Timeframe: 5 weeks overall (4 weeks of treatment and/or observations followed by a one-day visit at end of study in week 5)
| Intervention | score on a scale (Mean) | ||||
|---|---|---|---|---|---|
| Week 1 / Baseline | Week 2 | Week 3 | Week 4 | Week 5 / End | |
| Prontosan Solution and Gel | 2.41 | 1.74 | 1.51 | 1.25 | 1.30 |
2 reviews available for biguanides and Inflammation
| Article | Year |
|---|---|
Extending the TIME concept: what have we learned in the past 10 years?(*).
Topics: Abbreviations as Topic; Anti-Bacterial Agents; Anti-Infective Agents, Local; Anxiety; Bandages; Bigu | 2012 |
A comparison of agents used to manage type 2 diabetes mellitus: need for reappraisal of traditional approaches.
Topics: Animals; Benzamides; Biguanides; Blood Glucose; Diabetes Mellitus, Type 2; Glycated Hemoglobin; Glyc | 2004 |
3 trials available for biguanides and Inflammation
| Article | Year |
|---|---|
Inflammatory reaction, clinical efficacy, and safety of bacterial cellulose wound dressing containing silk sericin and polyhexamethylene biguanide for wound treatment.
Topics: Bandages; Biguanides; Cellulose; Disinfectants; Erythema; Female; Humans; Inflammation; Interleukin- | 2018 |
Effect of a wound cleansing solution on wound bed preparation and inflammation in chronic wounds: a single-blind RCT.
Topics: Aged; Aged, 80 and over; Bandages; Betaine; Biguanides; Chronic Disease; Female; Humans; Inflammatio | 2016 |
Effects of insulin dependence on inflammatory process, thrombotic mechanisms and endothelial function, in patients with type 2 diabetes mellitus and coronary atherosclerosis.
Topics: Aged; Biguanides; Blood Coagulation Factors; Coronary Artery Disease; Diabetes Mellitus, Type 2; Dru | 2007 |
7 other studies available for biguanides and Inflammation
| Article | Year |
|---|---|
Anti-fibrotic effect of pycnogenol® in a polyhexamethylene guanidine-treated mouse model.
Topics: Animals; Anti-Inflammatory Agents; Biguanides; Disease Models, Animal; Flavonoids; Inflammation; Mal | 2022 |
Anti-inflammatory effects of olanexidine gluconate on oral epithelial cells.
Topics: Anti-Inflammatory Agents; Biguanides; Epithelial Cells; Gingivitis; Glucuronates; Humans; Inflammati | 2019 |
Endotheliitis-A Presentation of Acanthamoeba Keratitis.
Topics: Acanthamoeba Keratitis; Administration, Ophthalmic; Adult; Antiprotozoal Agents; Benzamidines; Bigua | 2021 |
The safety and efficacy of bacterial nanocellulose wound dressing incorporating sericin and polyhexamethylene biguanide: in vitro, in vivo and clinical studies.
Topics: Adolescent; Adult; Aged; Animals; Bandages, Hydrocolloid; Biguanides; Cell Line; Cell Movement; Cell | 2016 |
In vitro inflammatory effects of polyhexamethylene biguanide through NF-κB activation in A549 cells.
Topics: A549 Cells; Biguanides; Cell Survival; Disinfectants; Inflammation; Interleukin-6; NF-kappa B; React | 2017 |
Effect of chlorhexidine gluconate on acute nonmicrobial inflammation reaction.
Topics: Animals; Biguanides; Chlorhexidine; Exudates and Transudates; Female; Gluconates; Inflammation; Leuk | 1978 |
Effect of chlorhexidine on gingival wound healing in the dog. A histometric study.
Topics: Animals; Biguanides; Biopsy; Chlorhexidine; Dental Plaque; Dogs; Gingiva; Gingivectomy; Gluconates; | 1975 |